Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory
| dc.authorid | 0000-0003-0052-1060 | |
| dc.contributor.author | Candan, Elif | |
| dc.contributor.author | Ülker, Zeynep | |
| dc.date.accessioned | 2026-11-19T07:14:30Z | |
| dc.date.available | 2026-11-19T07:14:30Z | |
| dc.date.issued | 2026 | |
| dc.department | Fakülteler, Diş Hekimliği Fakültesi, Temel Bilimler Bölümü | |
| dc.description.abstract | Background Dietary flavonoids have been proposed as partners for platinum chemotherapy, but their effects vary between tumour types, and sparing of normal cells has to be demonstrated. We examined gossypetin and luteolin, alone and combined with cisplatin, in MCF-7 breast and HeLa cervical carcinoma cells and in non-tumorigenic L929 fibroblasts. Methods and Results Cells were exposed to 100 µg/mL cisplatin (CP), gossypetin (GOS), luteolin (LUT) or their double and triple combinations. Viability was measured by MTT assay (technical triplicates, one experiment), combination effects by Bliss independence, Bax, Bcl-2 and CASP3 transcripts by RT-PCR (2−ΔΔCt), and phosphatidylserine exposure by Annexin V–Cy3 staining of archived micrographs. At 48 h, six of the seven treatments reduced MCF-7 viability (61.8–85.0% of control; Tukey-adjusted p≤0.018), gossypetin being the most active. Cisplatin plus luteolin exceeded the Bliss expectation in MCF-7 at 24 h (excess+0.11), whereas all combinations were less than additive at 48 h. No treatment reduced HeLa viability, and HeLa cells showed Bcl-2 induction (1.9–30.2-fold) with Bax repression (Bax/Bcl-2 ratio 0.03–0.21). L929 viability was not reduced at either time point, and the archived L929 field showed no Annexin V labelling. Conclusions At this single concentration, gossypetin- and luteolin-based treatments reduced MCF-7 viability without reducing L929 viability, while HeLa cells were refractory at the viability and transcript levels. These retrospective data support dose–response and protein-level studies rather than mechanistic conclusions. | |
| dc.identifier.citation | Candan, E., & Ülker, Z. (2026). Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory. Molecular Biology Reports, 53(1), Article 1898. | |
| dc.identifier.doi | 10.1007/s11033-026-13052-7 | |
| dc.identifier.issn | 0301-4851 | |
| dc.identifier.issue | 1 | |
| dc.identifier.pmid | 42980935 | |
| dc.identifier.scopus | 2-s2.0-105055873302 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12941/490 | |
| dc.identifier.volume | 53 | |
| dc.identifier.wosquality | Q3 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.institutionauthor | Ülker, Zeynep | |
| dc.institutionauthorid | 0000-0003-0052-1060 | |
| dc.language.iso | en | |
| dc.publisher | Springer | |
| dc.relation.ispartof | Molecular Biology Reports | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Gossypetin | |
| dc.subject | Luteolin | |
| dc.subject | Cisplatin | |
| dc.subject | Breast Cancer | |
| dc.subject | Bax/Bcl-2 | |
| dc.subject | Drug Combination | |
| dc.title | Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory | |
| dc.type | Article |
Dosyalar
Orijinal paket
1 - 1 / 1
Küçük Resim Yok
- İsim:
- Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory.pdf
- Boyut:
- 5.39 MB
- Biçim:
- Adobe Portable Document Format
Lisans paketi
1 - 1 / 1
Küçük Resim Yok
- İsim:
- license.txt
- Boyut:
- 1.17 KB
- Biçim:
- Item-specific license agreed upon to submission
- Açıklama:











